Company: RGNT
Filing Date: 2025-10-24
Form Type: F-1/A
Source: 0001213900-25-101900
Chunk: 190

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-10-24
Form: F-1/A
Chunk 190
---

 purchase up to 37,500 Ordinary Shares.                                                                                               |

<div align='center'>115

CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</div>

The following is a description
of the material terms of those transactions with related parties to which we are party.

Convertible Loans

In September of 2021, we
entered into several convertible loan agreements, or the 2021 CLAs, pursuant to which we obtained a convertible loan in the aggregate
amount of $835,000. In connection with the 2021 CLAs, the lenders were granted warrants to purchase shares of the Company of the same
class of the conversion securities. Effective as of March 11, 2024, the 2021 CLAs were converted into 88,385 Ordinary Shares and the
warrants granted thereunder expired in full in December 2023.

Between August 2020
and February 2021, we entered into the 2020 CLAs, pursuant to which we obtained a convertible loan in the aggregate amount of
$900,000. During September 2025, the 2020 CLAs have been extended until November 30, 2025. In October 2024, or the October 2024
Addendum, we proposed to the lenders under the 2020 CLAs to increase principal amount under their respective portion of the 2020
CLA, up to an additional aggregate amount of $450,000, so that the 2020 CLAs shall bear interest at 8% per annum until maturity
commencing as of July 1, 2024 with respect to non-participating lenders and March 31, 2025 with respect to participating lenders. In
addition, pursuant to the October 2024 Addendum, we agreed to pay the participating lenders at maturity an additional aggregate
amount of 340,000 as a risk premium, and upon the occurrence of an initial public offering based on a pre money valuation of $5.15
million, the 2020 CLAs shall be automatically converted into 609,888 Ordinary Shares and the Additional Amount in addition to the
risk premium and the Interest Amount (each as defined therein) shall be automatically converted into 553,640 Ordinary
Shares.

Other Financings

Between October 2024
and November 2024, we entered into bridge loan agreements, or the Bridge Loans, pursuant to which we obtained a bridge loan in the
total amount of $350,000